Burr bill, Novartis makeover, ALS update: a BioCentury podcast
Why Sen. Burr’s user fee bill demands urgency, plus updates on ALS, base editing and Novartis’ plans to revamp its commercial operations
By Jeff Cranmer, Executive Editor
July 19, 2022 1:27 AM UTC
Sen. Richard Burr’s new approach to a critical medical products user fee bill funding FDA must be taken seriously because the clock is ticking, and it’s ticking loudly, Washington Editor Steve Usdin said on the latest BioCentury This Week podcast. Usdin explains why Burr has introduced the bare-bones legislation and what’s at stake for industry in the weeks ahead.
This week’s podcast was sponsored by the BioCentury-BayHelix East-West Summit 2022, a gathering of biopharma executives and investors focused on building trusted cross-border relationships across the biopharma ecosystem. The VIP event takes place in the San Francisco Bay Area Nov. 14-16.For information on how to sponsor BioCentury This Week and The BioCentury Show, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.